CD38 and plasma cell myeloma: Malavasi et al. showed that the binding of DARA to CD38 on the cell surface results in the redistribution of CD38 into EVs from human myeloma cell lines, suggesting that CD38 levels on EVs may change during DARA treatment with the highest levels likely to be found following initial infusion of DARA [13].